Reneo Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financial Results And Business Update
March 28, 2024 07:35 ET
|
Reneo Pharmaceuticals, Inc.
IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a pharmaceutical company historically focused on the development and commercialization of therapies for...
Reneo Pharmaceuticals Announces Results from Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)
December 14, 2023 09:05 ET
|
Reneo Pharmaceuticals, Inc.
The STRIDE study did not meet its primary or secondary efficacy endpoint The company to suspend mavodelpar development and implement a workforce reduction IRVINE, Calif., Dec. 14, 2023 (GLOBE...
Reneo Pharmaceuticals Reports Third Quarter 2023 Financial Results
November 13, 2023 07:35 ET
|
Reneo Pharmaceuticals, Inc.
IRVINE, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies...
Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences
November 02, 2023 07:50 ET
|
Reneo Pharmaceuticals, Inc.
IRVINE, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies...
Reneo Pharmaceuticals Announces Poster Presentation at Upcoming Scientific Meetings
October 25, 2023 07:50 ET
|
Reneo Pharmaceuticals, Inc.
IRVINE, Calif., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies...
Reneo Pharmaceuticals Announces Last Patient Last Visit in the Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)
October 09, 2023 07:50 ET
|
Reneo Pharmaceuticals, Inc.
IRVINE, Calif., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies...
Reneo Pharmaceuticals to Participate in the Jefferies Biotech CNS/Neuro Summit
October 06, 2023 08:30 ET
|
Reneo Pharmaceuticals, Inc.
IRVINE, Calif., Oct. 06, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies...
Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences
August 29, 2023 07:35 ET
|
Reneo Pharmaceuticals, Inc.
IRVINE, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies...
Reneo Pharmaceuticals Reports Second Quarter 2023 Financial Results
August 10, 2023 07:35 ET
|
Reneo Pharmaceuticals, Inc.
IRVINE, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies...
Reneo Pharmaceuticals to Participate in SVB Securities Therapeutics Forum
June 30, 2023 08:25 ET
|
Reneo Pharmaceuticals, Inc.
IRVINE, Calif., June 30, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies...